with Kristen Fortney (@kpfortney), Jeff Kaditz (@jeffkaditz), David Sinclair (@davidasinclair), and Hanne Tidnam (@omnivorousread)
Even without a mythical fountain of youth, scientific advances have already dramatically increased how long humans live. But those advances to date have also largely been due to lower mortality rates, less infectious disease, and better nutrition. So when will modern medicine increase not just our healthspan, but our lifespan -- slowing down and possibly even reversing aging? What tools will it take? And what else, beyond the biology and technology involved, would change -- in our healthcare system and society as a whole?
In this episode of the a16z Podcast -- recorded at a16z's November 2017 Summit -- Kristen Fortney, CEO and cofounder of BioAge Labs; Jeff Kaditz, CEO and cofounder of Q.Bio; David Sinclair, Co-Director of the Paul F. Glenn Center for the Biology of Aging at Harvard Medical School; and Michael Snyder, Professor and Department Chair of Genetics at Stanford University (as well as co-founder of and advisor to Q.Bio), in conversation with Hanne Tidnam, break down the science from the science fiction around the topics of longevity, health, and aging.
image credit: Garry Knight/ Flickr
–––
The views expressed here are those of the individual AH Capital Management, L.L.C. (“a16z”) personnel quoted and are not the views of a16z or its affiliates. Certain information contained in here has been obtained from third-party sources, including from portfolio companies of funds managed by a16z. While taken from sources believed to be reliable, a16z has not independently verified such information and makes no representations about the enduring accuracy of the information or its appropriateness for a given situation.
This content is provided for informational purposes only, and should not be relied upon as legal, business, investment, or tax advice. You should consult your own advisers as to those matters. References to any securities or digital assets are for illustrative purposes only, and do not constitute an investment recommendation or offer to provide investment advisory services. Furthermore, this content is not directed at nor intended for use by any investors or prospective investors, and may not under any circumstances be relied upon when making a decision to invest in any fund managed by a16z. (An offering to invest in an a16z fund will be made only by the private placement memorandum, subscription agreement, and other relevant documentation of any such fund and should be read in their entirety.) Any investments or portfolio companies mentioned, referred to, or described are not representative of all investments in vehicles managed by a16z, and there can be no assurance that the investments will be profitable or that other investments made in the future will have similar characteristics or results. A list of investments made by funds managed by Andreessen Horowitz (excluding investments and certain publicly traded cryptocurrencies/ digital assets for which the issuer has not provided permission for a16z to disclose publicly) is available at https://a16z.com/investments/.
Charts and graphs provided within are for informational purposes solely and should not be relied upon when making any investment decision. Past performance is not indicative of future results. The content speaks only as of the date indicated. Any projections, estimates, forecasts, targets, prospects, and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others. Please see https://a16z.com/disclosures for additional important information.
a16z Podcast 